These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 36189209)

  • 1. SARS-CoV-2 neutralizing camelid heavy-chain-only antibodies as powerful tools for diagnostic and therapeutic applications.
    Schlör A; Hirschberg S; Amor GB; Meister TL; Arora P; Pöhlmann S; Hoffmann M; Pfaender S; Eddin OK; Kamhieh-Milz J; Hanack K
    Front Immunol; 2022; 13():930975. PubMed ID: 36189209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanobodies Protecting From Lethal SARS-CoV-2 Infection Target Receptor Binding Epitopes Preserved in Virus Variants Other Than Omicron.
    Casasnovas JM; Margolles Y; Noriega MA; Guzmán M; Arranz R; Melero R; Casanova M; Corbera JA; Jiménez-de-Oya N; Gastaminza P; Garaigorta U; Saiz JC; Martín-Acebes MÁ; Fernández LÁ
    Front Immunol; 2022; 13():863831. PubMed ID: 35547740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanobody engineering for SARS-CoV-2 neutralization and detection.
    Hannula L; Kuivanen S; Lasham J; Kant R; Kareinen L; Bogacheva M; Strandin T; Sironen T; Hepojoki J; Sharma V; Saviranta P; Kipar A; Vapalahti O; Huiskonen JT; Rissanen I
    Microbiol Spectr; 2024 Apr; 12(4):e0419922. PubMed ID: 38363137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Assessment of Serological Assays for SARS-CoV-2 as Surrogates for Authentic Virus Neutralization.
    Wohlgemuth N; Whitt K; Cherry S; Kirkpatrick Roubidoux E; Lin CY; Allison KJ; Gowen A; Freiden P; Allen EK; ; Gaur AH; Estepp JH; Tang L; Mori T; Hijano DR; Hakim H; McGargill MA; Krammer F; Whitt MA; Wolf J; Thomas PG; Schultz-Cherry S
    Microbiol Spectr; 2021 Oct; 9(2):e0105921. PubMed ID: 34704832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Naïve Phage Display Library-Derived Nanobody Neutralizes SARS-CoV-2 and Three Variants of Concern.
    Wu D; Cong J; Wei J; Hu J; Sun W; Ran W; Liao C; Zheng H; Ye L
    Int J Nanomedicine; 2023; 18():5781-5795. PubMed ID: 37869063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants.
    Chi X; Zhang X; Pan S; Yu Y; Shi Y; Lin T; Duan H; Liu X; Chen W; Yang X; Chen L; Dong X; Ren L; Ding Q; Wang J; Yang W
    Signal Transduct Target Ther; 2022 Feb; 7(1):44. PubMed ID: 35140196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
    Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer.
    Zhan W; Tian X; Zhang X; Xing S; Song W; Liu Q; Hao A; Hu Y; Zhang M; Ying T; Chen Z; Lan F; Sun L
    J Virol; 2022 Aug; 96(16):e0048022. PubMed ID: 35924918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Multivalent and Thermostable Nanobody Neutralizing SARS-CoV-2 Omicron (B.1.1.529).
    Lu Y; Li Q; Fan H; Liao C; Zhang J; Hu H; Yi H; Peng Y; Lu J; Chen Z
    Int J Nanomedicine; 2023; 18():353-367. PubMed ID: 36700149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Avidity engineering of human heavy-chain-only antibodies mitigates neutralization resistance of SARS-CoV-2 variants.
    Du W; Janssens R; Mykytyn AZ; Li W; Drabek D; van Haperen R; Chatziandreou M; Rissmann M; van der Lee J; van Dortmondt M; Martin IS; van Kuppeveld FJM; Hurdiss DL; Haagmans BL; Grosveld F; Bosch BJ
    Front Immunol; 2023; 14():1111385. PubMed ID: 36895554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereotypic neutralizing V
    Kim SI; Noh J; Kim S; Choi Y; Yoo DK; Lee Y; Lee H; Jung J; Kang CK; Song KH; Choe PG; Kim HB; Kim ES; Kim NJ; Seong MW; Park WB; Oh MD; Kwon S; Chung J
    Sci Transl Med; 2021 Jan; 13(578):. PubMed ID: 33397677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant.
    Schubert M; Bertoglio F; Steinke S; Heine PA; Ynga-Durand MA; Maass H; Sammartino JC; Cassaniti I; Zuo F; Du L; Korn J; Milošević M; Wenzel EV; Krstanović F; Polten S; Pribanić-Matešić M; Brizić I; Baldanti F; Hammarström L; Dübel S; Šustić A; Marcotte H; Strengert M; Protić A; Piralla A; Pan-Hammarström Q; Čičin-Šain L; Hust M
    BMC Med; 2022 Mar; 20(1):102. PubMed ID: 35236358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inference of SARS-CoV-2 spike-binding neutralizing antibody titers in sera from hospitalized COVID-19 patients by using commercial enzyme and chemiluminescent immunoassays.
    Valdivia A; Torres I; Latorre V; Francés-Gómez C; Albert E; Gozalbo-Rovira R; Alcaraz MJ; Buesa J; Rodríguez-Díaz J; Geller R; Navarro D
    Eur J Clin Microbiol Infect Dis; 2021 Mar; 40(3):485-494. PubMed ID: 33404891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A panel of nanobodies recognizing conserved hidden clefts of all SARS-CoV-2 spike variants including Omicron.
    Maeda R; Fujita J; Konishi Y; Kazuma Y; Yamazaki H; Anzai I; Watanabe T; Yamaguchi K; Kasai K; Nagata K; Yamaoka Y; Miyakawa K; Ryo A; Shirakawa K; Sato K; Makino F; Matsuura Y; Inoue T; Imura A; Namba K; Takaori-Kondo A
    Commun Biol; 2022 Jul; 5(1):669. PubMed ID: 35794202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike.
    Liu L; Wang P; Nair MS; Yu J; Rapp M; Wang Q; Luo Y; Chan JF; Sahi V; Figueroa A; Guo XV; Cerutti G; Bimela J; Gorman J; Zhou T; Chen Z; Yuen KY; Kwong PD; Sodroski JG; Yin MT; Sheng Z; Huang Y; Shapiro L; Ho DD
    Nature; 2020 Aug; 584(7821):450-456. PubMed ID: 32698192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination.
    Dapporto F; Marchi S; Leonardi M; Piu P; Lovreglio P; Decaro N; Buonvino N; Stufano A; Lorusso E; Bombardieri E; Ruello A; Viviani S; Molesti E; Trombetta CM; Manenti A; Montomoli E
    J Immunol Res; 2022; 2022():4813199. PubMed ID: 36093434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluorescent nanodiamond-based spin-enhanced lateral flow immunoassay for detection of SARS-CoV-2 nucleocapsid protein and spike protein from different variants.
    Wei-Wen Hsiao W; Sharma N; Le TN; Cheng YY; Lee CC; Vo DT; Hui YY; Chang HC; Chiang WH
    Anal Chim Acta; 2022 Oct; 1230():340389. PubMed ID: 36192062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of Concern.
    Favorskaya IA; Shcheblyakov DV; Esmagambetov IB; Dolzhikova IV; Alekseeva IA; Korobkova AI; Voronina DV; Ryabova EI; Derkaev AA; Kovyrshina AV; Iliukhina AA; Botikov AG; Voronina OL; Egorova DA; Zubkova OV; Ryzhova NN; Aksenova EI; Kunda MS; Logunov DY; Naroditsky BS; Gintsburg AL
    Front Immunol; 2022; 13():822159. PubMed ID: 35281053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of Nanosota-2, -3, and -4 as super potent and broad-spectrum therapeutic nanobody candidates against COVID-19.
    Ye G; Pan R; Bu F; Zheng J; Mendoza A; Wen W; Du L; Spiller B; Wadzinski BE; Liu B; Perlman S; Li F
    J Virol; 2023 Nov; 97(11):e0144823. PubMed ID: 37855638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.